nbm16yankees
12 minutes ago
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
Download as PDF
December 13, 2024
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
WALTHAM, Mass., Dec. 13, 2024 (GLOBE NE